Overall, results from the cardiovascular outcomes trials (CVOTs) completed for all marketed GLP-1 RAs in type 2 diabetes support a benefit in HF specifically in addition to the approved use in broad CVD risk reduction in people with type 2 diabetes (Sattar et al., 2021). This evidence concerns the gene GCG and type 2 diabetes mellitus.